Pathogenesis of Crimean-Congo hemorrhagic fever

Vector-Borne and Zoonotic Diseases

Volumn 13, Issue 7, 2013, Pages 429-437

  Akinci, Esragül ^a   Bodur, Hürrem ^a   Leblebicioglu, Hakan ^b  

^a ANKARA TRAINING AND RESEARCH HOSPITAL   (Turkey)

^b ONDOKUZ MAYIS UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

Author keywords

Crimean Congo hemorrhagic fever; Endothelial cells; Immunopathogenesis; Pathogenesis; Viral hemorrhagic fever

Indexed keywords

CYTOKINE; INTERFERON; VASCULAR ENDOTHELIAL CADHERIN; VIRUS ANTIBODY;

ADAPTIVE IMMUNITY; ANTIBODY RESPONSE; BLEEDING; BLOOD CLOTTING DISORDER; BLOOD VESSEL PERMEABILITY; CELL ACTIVATION; CRIMEAN CONGO HEMORRHAGIC FEVER; CYTOKINE RELEASE; DENDRITIC CELL; DISEASE SEVERITY; ENDOTHELIUM CELL; ERYTHROPHAGOCYTOSIS; HISTOPATHOLOGY; HUMAN; HYPOTENSION; LYMPHOCYTE; MACROPHAGE; MACROPHAGE ACTIVATION; MULTIPLE ORGAN FAILURE; NATURAL KILLER CELL; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; SHOCK; TIGHT JUNCTION; VASODILATATION; VIRUS ENTRY; VIRUS LOAD; VIRUS REPLICATION; ANIMAL; CONGO; IMMUNOLOGY; INNATE IMMUNITY; NAIROVIRUS; PATHOGENICITY; PATHOLOGY;

CRIMEAN-CONGO HEMORRHAGIC FEVER VIRUS; IXODIDA;

ANIMALS; ANTIBODIES, VIRAL; CONGO; HEMORRHAGIC FEVER VIRUS, CRIMEAN-CONGO; HEMORRHAGIC FEVER, CRIMEAN; HUMANS; IMMUNITY, INNATE; VIRUS REPLICATION;

EID: 84879973345     PISSN: 15303667     EISSN: 15577759     Source Type: Journal    
DOI: 10.1089/vbz.2012.1061     Document Type: Review

References (73)

1. Akinci E, Yilmaz M, Bodur H, Ongürü P, et al. Analysis of lymphocyte subgroups in Crimean-Congo hemorrhagic fever. Int J Infect Dis 2009; 13:560-563.
2. Altaf A, Luby S, Ahmed AJ, Zaidi N, et al. Outbreak of Crimean-Congo haemorrhagic fever in Quetta, Pakistan: Contact tracing and risk assessment. Trop Med Int Health 1998; 3:878-882.
3. Andersson I, Karlberg H, Mousavi-Jazi M, Martínez-Sobrido L, et al. Crimean-Congo hemorrhagic fever virus delays activation of the innate immune response. J Med Virol 2008; 80:1397-1404.
4. Ascioglu S, Leblebicioglu H, Vahaboglu H, Chan KA. Ribavirin for patients with Crimean-Congo haemorrhagic fever: A systematic review and meta-analysis. J Antimicrob Chemother 2011; 66:1215-1222.
5. Athar MN, Khalid MA, Ahmad AM, Bashir N, et al. Crimean-Congo hemorrhagic fever outbreak in Rawalpindi, Pakistan, February 2002: Contact tracing and risk assessment. Am J Trop Med Hyg 2005; 72:471-473.
6. Bakir M, Ugurlu M, Dokuzoguz B, Bodur H, et al.; Turkish CCHF Study Group. Crimean-Congo haemorrhagic fever outbreak in Middle Anatolia: A multicentre study of clinical features and outcome measures. J Med Microbiol 2005; 54:385-389.
7. Baskerville A, Satti A, Murphy FA, Simpson DI. Congo-Crimean haemorrhagic fever in Dubai: Histopathological studies. J Clin Pathol 1981; 34:871-874.
8. Bente DA, Alimonti JB, Shieh WJ, Camus G, et al. Pathogenesis and immune response of Crimean-Congo hemorrhagic fever virus in a STAT-1 knockout mouse model. J Virol 2010; 84:11089-11100.
9. Bereczky S, Lindegren G, Karlberg H, Akerström S, et al. Crimean-Congo hemorrhagic fever virus infection is lethal for adult type I interferon receptor-knockout mice. J Gen Virol 2010; 91:1473-1477.
10. Bodur H, Akinci E, Ongü rü P, Uyar Y, et al. Evidence of vascular endothelial damage in Crimean-Congo hemorrhagic fever. Int J Infect Dis 2010; 14:e704-e707.
11. Bodur H, Erbay A, Akinci E, Öngürü P, et al. Effect of oral ribavirin treatment on the viral load and disease progression in Crimean-Congo hemorrhagic fever. Int J Infect Dis 2011; 15:e44-e47.
12. Bodur H, Akinci E, Ascioglu S, Ongürü P, Uyar Y. Subclinical infections with Crimean-Congo hemorrhagic fever virus, Turkey, Emerg Infect Dis 2012;18:640-642.
13. Bouma BN, Meijers JC. New insights into factors affecting clot stability: A role for thrombin activatable fibrinolysis inhibitor (TAFI; plasma procarboxypeptidase B, plasma procarbox-ypeptidase U, procarboxypeptidase R). Semin Hematol 2004; 41(1 Suppl 1):13-19.
14. Burt FJ, Swanepoel R, Shieh WJ, Smith JF, et al. Im-munohistochemical and in situ localization of Crimean-Congo hemorrhagic fever (CCHF) virus in human tissues and implications for CCHF pathogenesis. Arch Pathol Lab Med 1997; 121:839-846.
15. Cagatay A, Kapmaz M, Karadeniz A, Basaran S, et al. Haemo-phagocytosis in a patient with Crimean Congo haemorrhagic fever. J Med Microbiol 2007; 56:1126-1128.
16. Cevik MA, Erbay A, Bodur H, Eren SS, et al. Viral load as a predictor of outcome in Crimean-Congo hemorrhagic fever. Clin Infect Dis 2007; 45:e96-e100.
17. Cevik MA, Erbay A, Bodur H, Gülderen E, et al. Clinical and laboratory features of Crimean-Congo hemorrhagic fever: Predictors of fatality. Int J Infect Dis 2008; 12:374-379.
18. Chaturvedi UC, Dhawan R, Khanna M, Mathur A. Breakdown of the blood-brain barrier during dengue virus infection of mice. J Gen Virol 1991; 72:859-866.
19. Chen JP, Cosgriff TM. Hemorrhagic fever virus-induced changes in hemostasis and vascular biology. Blood Coagul Fibrinolysis 2000; 11:461-483.
20. Chinikar S, Ghiasi SM, Moradi M, Goya MM, et al. Phylogenetic analysis in a recent controlled outbreak of Crimean-Congo haemorrhagic fever in the south of Iran, December 2008. Euro Surveill 2010; 15(47):pii:19720.
21. Connolly-Andersen AM. Pathogenesis of an emerging pathogen-Crimean-Congo hemorrhagic fever. Thesis, Stockholm, 2010.
22. Connolly-Andersen AM, Magnusson KE, Mirazimi A. Basolateral entry and release of Crimean-Congo hemorrhagic fever virus in polarized MDCK-1 cells. J Virol 2007; 81:2158-2164.
23. Connolly-Andersen AM, Douagi I, Kraus AA, Mirazimi A. Crimean Congo hemorrhagic fever virus infects human monocyte-derived dendritic cells. Virology 2009; 390:157-162.
24. Connolly-Andersen AM, Moll G, Andersson C, Akerström S, et al. Crimean-Congo hemorrhagic fever virus activates en-dothelial cells. J Virol 2011; 85:7766-7774.
25. Deyde VM, Khristova ML, Rollin PE, Ksiazek TG, et al. Crimean-Congo hemorrhagic fever virus genomics and global diversity. J Virol 2006; 80:8834-8842.
26. Domingues RB, Kuster GW, Onuki-Castro FL, Souza VA, et al. Involvement of the central nervous system in patients with dengue virus infection. J Neurol Sci 2008; 15:36-40.
27. Duh D, Saksida A, Petrovec M, Ahmeti S, et al. Viral load as predictor of Crimean-Congo hemorrhagic fever outcome. Emerg Infect Dis 2007; 13:1769-1772.
28. Elaldi N, Bodur H, Ascioglu S, Celikbas A, et al. Efficacy of oral ribavirin treatment in Crimean-Congo haemorrhagic fever: A quasi-experimental study from Turkey. J Infect 2009; 58:238-244.
29. Ergonul O, Celikbas A, Baykam N, Eren S, et al. Analysis of risk-factors among patients with Crimean-Congo haemorrhagic fever virus infection: Severity criteria revisited. Clin Microbiol Infect 2006a; 12:551-554.
30. Ergonul O, Tuncbilek S, Baykam N, Celikbas A, et al. Evaluation of serum levels of interleukin (IL)-6, IL-10, and tumor necrosis factor-alpha in patients with Crimean-Congo hemorrhagic fever. J Infect Dis 2006b; 193:941-944.
31. Favara BE. Hemophagocytic lymphohistiocytosis: A hemopha-gocytic syndrome. Semin Diagn Pathol 1992; 9:63-74.
32. Fisman DN. Hemophagocytic syndromes and infection. Emerg Infect Dis 2000; 6:601-608.
33. Geisbert TW, Hensley LE, Gibb TR, Steele KE, et al. Apoptosis induced in vitro and in vivo during infection by Ebola and Marburg viruses. Lab Invest 2000; 80:171-186.
34. Gunther S, Weisner B, Roth A, Grewing T, et al. Lassa fever encephalopathy: Lassa virus in cerebrospinal fluid but not in serum. J Infect Dis 2001; 184:345-349.
35. Habjan M, Andersson I, Klingström J, Schümann M, et al. Processing of genome 5¢ termini as a strategy of negative-strand RNA viruses to avoid RIG-I-dependent interferon induction. PLoS One 2008; 3:e2032.
36. Haferkamp S, Fernando L, Schwarz TF, Feldmann H, et al. In-tracellular localization of Crimean-Congo hemorrhagic fever (CCHF) virus glycoproteins. Virol J 2005; 2:42.
37. Hatipoglu CA, Bulut C, Yetkin MA, Ertem GT, et al. Evaluation of clinical and laboratory predictors of fatality in patients with Crimean-Congo haemorrhagic fever in a tertiary care hospital in Turkey. Scand J Infect Dis 2010; 42:516-521.
38. Jamil B, Hasan RS, Sarwari AR, Burton J, et al. Crimean-Congo hemorrhagic fever: Experience at a tertiary care hospital in Karachi, Pakistan. Trans R Soc Trop Med Hyg 2005; 99:577-584.
39. Joubert JR, King JB, Rossouw DJ, Cooper R. A nosocomial outbreak of Crimean-Congo haemorrhagic fever at Tygerberg Hospital. Part III. Clinical pathology and pathogenesis. S Afr Med J 1985; 68:722-728.
40. Kang SS, McGavern DB. Microbial induction of vascular pathology in the CNS. J Neuroimmune Pharmacol 2010; 5:370-386.
41. Karti SS, Odabasi Z, Korten V, Yilmaz M, et al. Crimean-Congo hemorrhagic fever in Turkey. Emerg Infect Dis 2004; 10:1379-1384.
42. Kubar A, Haciomeroglu M, Ozkul A, Bagriacik U, et al. Prompt administration of Crimean-Congo hemorrhagic fever (CCHF) virus hyperimmunoglobulin in patients diagnosed with CCHF and viral load monitorization by reverse transcriptase-PCR. Jpn J Infect Dis 2011; 64:439-443.
43. Leblebicioglu H. Crimean-Congo haemorrhagic fever in Eurasia. Int J Antimicrob Agents 2010; 36(Suppl 1):S43-S46.
44. Leblebicioglu H, Bodur H, Dokuzoguz B, Elaldi N, et al. Case management and supportive treatment for patients with Crimean-Congo hemorrhagic fever. Vector Borne Zoonotic Dis 2012; 12:805-811.
45. Leeuwenberg JF, Smeets EF, Neefjes JJ, Shaffer MA, et al. E-selectin and intercellular adhesion molecule-1 are released by activated human endothelial cells in vitro. Immunology 1992; 77:543-549.
46. Ozkurt Z, Kiki I, Erol S, Erdem F, et al. Crimean-Congo hem-orrhagic fever in Eastern Turkey: Clinical features, risk factors and efficacy of ribavirin therapy. J Infect 2006; 52:207-215.
47. Ozturk B, Kuscu F, Tutuncu E, Sencan I, et al. Evaluation of the association of serum levels of hyaluronic acid, sICAM-1, sVCAM-1, and VEGF-A with mortality and prognosis in patients with Crimean-Congo hemorrhagic fever. J Clin Virol 2010; 47:115-119.
48. Paes MV, Pinhão AT, Barreto DF, Costa SM, et al. Liver injury and viremia in mice infected with dengue-2 virus. Virology 2005; 338:236-246.
49. Paes MV, Lenzi HL, Nogueira ACM, Nuovo GJ, et al. Hepatic damage associated with dengue-2 virus replication in liver cells of BALB/c mice. Laboratory Invest 2009; 89: 1140-1151.
50. Papa A, Bino S, Velo E, Harxhi A, et al. Cytokine levels in Crimean-Congo hemorrhagic fever. J Clin Virol 2006; 36: 272-276.
51. Peters CJ, Zaki SR. Role of the endothelium in viral hemorrhagic fevers. Crit Care Med 2002; 30(5 Suppl):S268-S273.
52. Petrache I, Birukova A, Ramirez SI, Garcia JG, et al. The role of the microtubules in tumor necrosis factor-alpha-induced en-dothelial cell permeability. Am J Respir Cell Mol Biol 2003; 28:574-581.
53. Peyrefitte CN, Perret M, Garcia S, Rodrigues R, et al. Differential activation profiles of Crimean-Congo hemorrhagic fever virusand Dugbe virus-infected antigen-presenting cells. J Gen Virol 2010; 91:189-198.
54. Rodrigues R, Paranhos-Baccala'G, Vernet G, Peyrefitte CN. Crimean-Congo hemorrhagic fever virus-infected hepatocytes induce ER-stress and apoptosis crosstalk. PLoS One 2012; 7:e29712.
55. Saksida A, Duh D, Wraber B, Dedushaj I, et al. Interacting roles of immune mechanisms and viral load in the pathogenesis of crimean-congo hemorrhagic fever. Clin Vaccine Immunol 2010; 17:1086-1093.
56. Samuel CE. Antiviral actions of interferons. Clin Microbiol Rev 2001; 14:778-809.
57. Schnittler HJ, Feldmann H. Viral hemorrhagic fever-a vascular disease? Thromb Haemost 2003; 89:967-972.
58. Sonmez M, Aydin K, Durmus A, Sucu N, et al. Plasma activity of thrombin activatable fibrinolysis inhibitor in Crimean-Congo hemorrhagic fever. J Infect 2007; 55:184-187.
59. Swanepoel R, Gill DE, Shepherd AJ, Leman PA, et al. The clinical pathology of Crimean-Congo hemorrhagic fever. Rev Infect Dis 1989; 11(Suppl 4):S794-S800.
60. Tasdelen Fisgin N, Fisgin T, Tanyel E, Doganci L, et al. Crimean-Congo hemorrhagic fever: five patients with hemophagocytic syndrome. Am J Hematol 2008; 83:73-76.
61. van Gorp EC, Suharti C, ten Cate H, Dolmans WM, et al. Review: Infectious diseases and coagulation disorders. J Infect Dis 1999; 180:176-186.
62. Venkiteswaran K, Xiao K, Summers S, Calkins CC, et al. Regulation of endothelial barrier function and growth by VE-cadherin, plakoglobin, and beta-catenin. Am J Physiol Cell Physiol 2002; 283:C811-C821.
63. Videm V, Albrigtsen M. Soluble ICAM-1 and VCAM-1 as markers of endothelial activation. Scand J Immunol 2008; 67:523-531.
64. Vincent PA, Xiao K, Buckley KM, Kowalczyk AP. VE-cadherin: Adhesion at arm's length. Am J Physiol Cell Physiol 2004; 286:C987-C997.
65. Vorou R, Pierroutsakos IN, Maltezou HC. Crimean-Congo hemorrhagic fever. Curr Opin Infect Dis 2007; 20:495-500.
66. Warfield KL, Bradfute SB, Wells J, Lofts L, et al. Development and characterization of a mouse model for Marburg hemor-rhagic fever. J Virol 2009; 83:6404-6415.
67. Weber F, Mirazimi A. Interferon and cytokine responses to Crimean Congo hemorrhagic fever virus; an emerging and neglected viral zonoosis. Cytokine Growth Factor Rev 2008; 19:395-404.
68. Weber F, Wagner V, Rasmussen SB, Hartmann R, et al. Double-stranded RNA is produced by positive-strand RNA viruses and DNA viruses but not in detectable amounts by negativestrand RNA viruses. J Virol 2006; 80:5059-5064.
69. Whitehouse CA. Crimean-Congo hemorrhagic fever. Antiviral Res 2004; 64:145-160.
70. Wölfel R, Paweska JT, Petersen N, Grobbelaar AA, et al. Virus detection and monitoring of viral load in Crimean-Congo hemorrhagic fever virus patients. Emerg Infect Dis 2007; 13:1097-1100.
71. Xiao X, Feng Y, Zhu Z, Dimitrov DS. Identification of a putative Crimean-Congo hemorrhagic fever virus entry factor. Bio-chem Biophys Res Commun 2011; 411:253-258.
72. Yilmaz M, Aydin K, Akdogan E, Sucu N, et al. Peripheral blood natural killer cells in Crimean-Congo hemorrhagic fever. J Clin Virol 2008; 42:415-417.
73. Yilmaz GR, Buzgan T, Irmak H, Safran A, et al. The epidemiology of Crimean-Congo hemorrhagic fever in Turkey, 2002-2007. Int J Infect Dis 2009; 13:380-386.